​

CalciMedica Stock (NASDAQ:CALC)

RevenueOwnershipFinancialsChart
CalciMedica by TradingView

Previous Close

$4.63

52W Range

$1.42 - $4.82

50D Avg

$3.40

200D Avg

$2.55

Market Cap

$66.72M

Avg Vol (3M)

$67.58K

Beta

1.12

Div Yield

-

CALC Company Profile

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jun 14, 2023

Website

CALC Performance

CALC Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-24.20M$-21.88M$-36.18M
Net Income$-13.70M$-34.36M$-35.60M
EBITDA$-24.20M$-34.19M$-7.64M
Basic EPS-$-7.65$-23.20
Diluted EPS-$-7.65$-23.20

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
TVRDTvardi Therapeutics, Inc.
ELUTElutia Inc.
LVTXLAVA Therapeutics N.V.
XLOXilio Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
RVPHReviva Pharmaceuticals Holdings, Inc.
RNXTRenovoRx, Inc.
LTRNLantern Pharma Inc.